What is MBF Bioscience?
MBF Bioscience operates at the intersection of advanced microscopy and quantitative data analysis, providing essential tools for neuroscientists and medical researchers. The company is widely recognized for its flagship software platforms, including Neurolucida and Stereo Investigator, which facilitate complex tasks such as neuron reconstruction and stereological analysis. By bridging the gap between raw imaging data and actionable scientific insights, MBF Bioscience serves a critical role in academic and clinical research environments. Their commitment to engineering robust, cost-effective solutions has established them as a foundational partner for laboratories seeking to push the boundaries of biological discovery through high-fidelity imaging and automated analysis workflows.
How much funding has MBF Bioscience raised?
MBF Bioscience has raised a total of $350K across 1 funding round:
Debt
$350K
Debt (2020): $350K with participation from PPP
Key Investors in MBF Bioscience
PPP
Public-Private Partnership
What's next for MBF Bioscience?
With the successful acquisition of this late-stage capital, MBF Bioscience is well-positioned to accelerate its product development roadmap and expand its footprint in the medical education and research sectors. The strategic focus will likely shift toward enhancing the integration of artificial intelligence within their existing imaging suites, thereby increasing the throughput and accuracy of complex biological measurements. As the demand for sophisticated quantitative imaging solutions continues to rise, the company is poised to leverage its recent financing to deepen its service offerings, including custom software development and specialized training programs. This trajectory suggests a sustained commitment to innovation, ensuring that MBF Bioscience remains a primary architect of the tools that define modern bioscience research.
See full MBF Bioscience company page
